Cooper Financial Group Decreases Position in AstraZeneca PLC (NASDAQ:AZN)

Cooper Financial Group decreased its stake in AstraZeneca PLC (NASDAQ:AZN) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,467 shares of the company’s stock after selling 1,167 shares during the quarter. Cooper Financial Group’s holdings in AstraZeneca were worth $882,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter worth about $26,000. Capital Performance Advisors LLP purchased a new position in shares of AstraZeneca during the 3rd quarter worth about $28,000. Groupama Asset Managment grew its holdings in AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in AstraZeneca in the 3rd quarter worth about $45,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AstraZeneca stock opened at $65.73 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The company has a market capitalization of $203.80 billion, a PE ratio of 31.45, a P/E/G ratio of 1.19 and a beta of 0.46. The company has a 50 day moving average price of $66.00 and a 200-day moving average price of $74.78. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.87 EPS. As a group, equities analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.